open access

Vol 50, No 3 (2012)
Original paper
Submitted: 2012-10-08
Accepted: 2012-10-08
Published online: 2012-10-08
Get Citation

Expression of metallothionein I/II and Ki-67 antigen in various histological types of basal cell carcinoma

Andrzej Bieniek, Bartosz Pula, Aleksandra Piotrowska, Marzena Podhorska-Okolow, Anna Salwa, Maria Koziol, Piotr Dziegiel
DOI: 10.5603/FHC.2012.0048
·
Folia Histochem Cytobiol 2012;50(3):352-357.

open access

Vol 50, No 3 (2012)
ORIGINAL PAPERS
Submitted: 2012-10-08
Accepted: 2012-10-08
Published online: 2012-10-08

Abstract

Basal cell carcinoma (BCC) is the most frequent skin cancer, with many different histological subtypes.
Recent studies have investigated the expression of proliferative markers, but little is known about the
expression of metallothioneins (MT) in different histological subtypes of this cancer and their impact on proliferation
intensity in BCC. In this study, we examined MT-I/II expression by immunohistochemistry in 58 different
histological subtypes of BCC (38 nodular, six adenoid, eight infiltrative, and six metatypic cases) and correlated
its expression with tumor size and Ki-67 proliferation rate. Statistical analysis revealed no significant differences
in the expression of studied markers in regard to the histological subtype. A positive correlation between
MT and Ki-67 expression was observed for all the studied cases (r = 0.26; p = 0.049), but was even
stronger in the metatypic subtype of BCC (r = 0.85; p = 0.033). MT and Ki-67 expression did not correlate with
tumor size. In conclusion, it seems that metallothioneins may have an impact on the proliferation rate of BCC,
but further studies are required to determine whether MT may be a risk factor of recurrences.

Abstract

Basal cell carcinoma (BCC) is the most frequent skin cancer, with many different histological subtypes.
Recent studies have investigated the expression of proliferative markers, but little is known about the
expression of metallothioneins (MT) in different histological subtypes of this cancer and their impact on proliferation
intensity in BCC. In this study, we examined MT-I/II expression by immunohistochemistry in 58 different
histological subtypes of BCC (38 nodular, six adenoid, eight infiltrative, and six metatypic cases) and correlated
its expression with tumor size and Ki-67 proliferation rate. Statistical analysis revealed no significant differences
in the expression of studied markers in regard to the histological subtype. A positive correlation between
MT and Ki-67 expression was observed for all the studied cases (r = 0.26; p = 0.049), but was even
stronger in the metatypic subtype of BCC (r = 0.85; p = 0.033). MT and Ki-67 expression did not correlate with
tumor size. In conclusion, it seems that metallothioneins may have an impact on the proliferation rate of BCC,
but further studies are required to determine whether MT may be a risk factor of recurrences.
Get Citation
About this article
Title

Expression of metallothionein I/II and Ki-67 antigen in various histological types of basal cell carcinoma

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 3 (2012)

Article type

Original paper

Pages

352-357

Published online

2012-10-08

Page views

2688

Article views/downloads

2178

DOI

10.5603/FHC.2012.0048

Bibliographic record

Folia Histochem Cytobiol 2012;50(3):352-357.

Authors

Andrzej Bieniek
Bartosz Pula
Aleksandra Piotrowska
Marzena Podhorska-Okolow
Anna Salwa
Maria Koziol
Piotr Dziegiel

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl